Non-sepsis Critical Illness Group: Critical illness (including severe trauma, post-major surgery, multiple organ dysfunction, etc., non-infectious etiology)Sepsis Critical Illness Group: Sepsis (meeting the Sepsis-3 criteria, defined as organ dysfunction resulting from infection)
Conditions
Interventions
Non-septic critical illness (e.g., severe trauma, major surgery, etc.):none
Healthy control:none
Septic Critical Illness:none
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Healthy control group: (1) Age >=18 years old; (2) No acute or chronic major diseases; (3) Sign a written informed consent form. 2. Non-sepsis critical care group: (1) Age >=18 years old; (2) Admitted to the ICU, meeting the criteria for critical illness; (3) Exclusion of Sepsis by Sepsis-3 criteria; (4) Sign a written informed consent form (either by oneself or by a legally authorized agent). 3. Sepsis Critical Care Group: (1) Age >=18 years old; (2) Admitted to the ICU, meeting the Sepsis-3 criteria; (3) Sign a written informed consent form (either by oneself or by a legally authorized agent).
Exclusion criteria
Exclusion criteria: 1. Age 1 mg/kg/d prednisone equivalent) before or within 24 hours after admission to the ICU; 4. Have used immune checkpoint inhibitors (such as anti-PD-1 /PD-L1/CTLA-4 antibodies) recently (<6 weeks); 5. The estimated length of stay in the ICU is less than 24 hours or there is a risk of immediate death. 6. Pregnant or lactating women; 7. There is active massive hemorrhage; 8. Informed consent cannot be obtained.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation between glycolytic capacity of ?d T cells and 28-day mortality;Correlation between glycolytic capacity of ?d T cells and 90-day mortality;Glycolytic capacity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Mitochondrial membrane potential of ?d T cells;28-day mortality;Rectal swab collection-related discomfort;Correlation between ?d T cell glycolytic capacity and lactate level;PD-1 expression on ?d T cells;Correlation between ?d T cell glycolytic capacity and vasopressor dose;Correlation between ?d T cell glycolytic capacity and SOFA score;ICU mortality;Effector function of ?d T cells (cytokine secretion);Abundance of specific bacterial genera (e.g., short-chain fatty acid-producing bacteria);CD69 expression on ?d T cells;LAG-3 expression on ?d T cells;Gut microbiota alpha diversity;90-day mortality;Ki67 expression on ?d T cells;TIM-3 expression on ?d T cells;Length of hospital stay;Gut microbiota beta diversity;Correlation between ?d T cell glycolytic capacity and APACHE ? score;Correlation between fecal metabolites and ?d T cell glycolytic capacity;Mitochondrial reactive oxygen species (mtROS) level of ?d T cells;Fecal metabolites (short-chain fatty acids, bile acids);In-hospital mortality;Blood sampling-related adverse events; | — |
Countries
China
Contacts
Public ContactZhang Jiancheng
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed